FDA approves Pfizer's Humira biosimilar, offers update on progress biosimilar approvalsPfizer plans to launch Humira biosimilar in 2023. Study: USP quality standards support U.S. generics marketPublic quality standards set forth by USP increased competition in the generic medicines market and reduced overall prescription drug costs by $11 billion in 2015 and 2016. Fresenius Kabi introduces generic Emend Fresenius Kabi's generic Emend provides clinicians with a treatment alternative that has a 24-month shelf life. Teva taps Eli Kalif as executive vice president, CFO Eli Kalif will join Teva as executive vice president and chief financial officer on Dec. 22. Breckenridge gets FDA green light for generic Tarceva Tarceva and its generics had a market value of approximately $145 million during the year ended Sept, 30, 2019. Glenmark gets FDA nod for generic Epiduo Epiduo gel had a market value of about $33.7 million for the 12 month period ended September 2019, according to IQVIA. Fresenius Kabi launches small-volume prefilled heparin sodium syringes Fresenius Kabi is expanding its heparin and Simplist prefilled syringe portfolio with the addition of a small-volume presentation of Heparin. Teva, Celltrion launch their Rituxan biosimilar Truxima Teva and Celltrion's Truxima is the first biosimilar to Genentech’s Rituxan (rituximab). Sandoz gets FDA green light for Neulasta biosimilar Ziextenzo With the FDA approval of Ziextenzo — a biosimilar of Neulasta — Sandoz is the first and only company to offer long- and short-acting filgrastim biosimilar treatment options. FDA approves third indication for Lupin’s generic Levoxyl Lupin's levothyroxine sodium tablets now is approved as a generic of Synthroid, Unithroid, and Levoxyl. First Previous 172 173 174 175 176 Next Last
